#4610 LACK OF EFFICACY AND SAFETY OF ECULIZUMAB FOR TREATMENT OF ANTIBODY-MEDIATED REJECTION FOLLOWING RENAL TRANSPLANTATION
نویسندگان
چکیده
Abstract Background and Aims We evaluated the efficacy safety of eculizumab in comparison with plasmapheresis intravenous immunoglobulin therapy renal transplant recipients diagnosed antibody-mediated rejection (AMR). Method This was a multicenter, open-label, prospective, randomized analysis. The patients were by type (eg, infusions or standard care [SOC]: plasmapheresis/intravenous immunoglobulin). (ie, arm: 7 patients, SOC 4 patients) for continued presence donor-specific antibodies (DSAs) C4d (staining on biopsy), as well histologic evidence, using repeat biopsy after treatment. Results allograft biopsies revealed that did not prevent progression to glomerulopathy. Cases AMR early post-transplantation period 2 (eculizumab 1 patient, patient) late 9 patients. Most reports show eculizumab, combination other therapeutic measures such PP and/or IVIG, effectively reversed rejection. However, alone could treat effectively. Only arm experienced reversal, no graft losses occurred either group. After treatment, DSA titers generally decreased compared taken at time diagnosis. There serious adverse effects arm. Conclusion Eculizumab cannot does acute from progressing chronic it should be considered potential alternative because may associated levels.
منابع مشابه
comparison of zoe and vitapex for canal treatment of necrotic primary teeth
چکیده ندارد.
15 صفحه اولthe innovation of a statistical model to estimate dependable rainfall (dr) and develop it for determination and classification of drought and wet years of iran
آب حاصل از بارش منبع تأمین نیازهای بی شمار جانداران به ویژه انسان است و هرگونه کاهش در کم و کیف آن مستقیماً حیات موجودات زنده را تحت تأثیر منفی قرار می دهد. نوسان سال به سال بارش از ویژگی های اساسی و بسیار مهم بارش های سالانه ایران محسوب می شود که آثار زیان بار آن در تمام عرصه های اقتصادی، اجتماعی و حتی سیاسی- امنیتی به نحوی منعکس می شود. چون میزان آب ناشی از بارش یکی از مولفه های اصلی برنامه ...
15 صفحه اولEculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
Thrombotic microangiopathy is a form of antibody-mediated rejection (ABMR): it is the main complication of ABO-incompatible (ABOi) kidney transplantation (KT). Herein, we report on two cases of ABMR with biological and histological features of thrombotic microangiopathy (TMA) that were treated by eculizumab after ABOi KT. The first patient presented with features of TMA at postoperative day (PO...
متن کاملTreatment of Antibody-mediated Rejection in Kidney Transplantation
Antibody-mediated rejection (AMR) is a relatively rare but severe complication in kidney transplantation associated with increased risk of graft loss. Diagnosis of acute and chronic AMR is based on typical histological hallmarks, deposition of C4d in peritubular capillaries and presence of donor-specific antibodies (DSA). Many novel and attractive treatment options have become available in rece...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephrology Dialysis Transplantation
سال: 2023
ISSN: ['1460-2385', '0931-0509']
DOI: https://doi.org/10.1093/ndt/gfad063c_4610